

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: April 10, 2012
(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada	000-54402	91-1835664
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification Number)
555 Heritage Drive, Jupiter, Florida	33458	
(Address of Principal Executive Offices)	(Zip Code)	

Registrant's telephone number, including area code: (561) 904-6070

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On April 10, 2012, BioRestorative Therapies, Inc. (the “Company”) issued a press release (the “Financing Press Release”) announcing that it has obtained \$2,100,000 in private financing during 2012. A copy of the Press Release is furnished as Exhibit 99.1 hereto.

On April 11, 2012, the Company issued a press release (the “Regenerative Press Release” and together with the Financing Press Release, the “Press Releases”) announcing that its License Agreement with Regenerative Sciences, LLC has become effective. A copy of the Regenerative Press Release is furnished as Exhibit 99.2 hereto.

The information in the Press Releases is being furnished, not filed, pursuant to this Item 8.01. Accordingly, the information in the Press Releases will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Report is not intended to, and does not, constitute a determination or admission by the Company that the information in this Report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated April 10, 2012, issued by BioRestorative Therapies, Inc.

99.2 Press Release, dated April 11, 2012, issued by BioRestorative Therapies, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES, INC.

Dated: April 11, 2012

By: /s/ Mark Weinreb

Mark Weinreb

Chief Executive Officer



News Release

BioRestorative Therapies Obtains \$2.1 Million In 2012 Private Financing

Jupiter, Fla. – April 10, 2012 – BioRestorative Therapies, Inc. (“BRT” or the “Company”) (OTCQB: BRTX), a life sciences company focused on cellular therapies for various personal medical applications, announced today that it has completed multiple rounds of private financing in 2012 totaling approximately \$2,100,000. A total of approximately \$1,600,000 was received as debt financing and an additional \$500,000 was raised as equity.

Pursuant to the equity and note financing, the Company issued approximately 22,000,000 shares of restricted stock and 25,500,000 five year warrants to purchase BRT stock at prices between \$0.03 - \$0.035 per share. The debt is repayable over a period of six to twelve months with interest at the rate of 15% per annum.

“I am extremely pleased with the Company’s continued growth as well as our ability to maintain consistent interest from investors and shareholders,” commented BioRestorative Therapies CEO, Mark Weinreb. “This financing provides the Company with resources to further advance our previously announced initiatives.”

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a medical center of excellence using cell and tissue protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. In June 2011, the Company launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem™ Program. The ThermoStem™ Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for clinical procedures and outcomes for future personal medical applications. The Company also offers facial creams and products under the Stem Pearls® brand.

#####

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:

KCSA Strategic Communications

Philip Carlson / Josh Dver

+1 212.896.1233 / +1 212.896.1239

pcarlson@kcsa.com / jdver@kcsa.com



News Release

BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure

*Agreement Provides the Company with Three New Potential
Sources for Revenues*

Jupiter, Fla. – April 11, 2012 – BioRestorative Therapies, Inc. (“BRT” or the “Company”) (OTCQB: BRTX), a life sciences company focused on cellular therapies for various personal medical applications, announced today it has closed on the previously announced license agreement with Regenerative Sciences, LLC for the licensing of a technique used for the treatment of bulging and herniated discs. This treatment encompasses a novel way of cell culturing and includes a medical device designed for the re-plantation of an individual’s own stem cells into the disc area for repair.

The license agreement provides the Company with three new potential revenue streams: the sale or licensing of the specialized medical device, the laboratory work needed to prepare the cells, and sublicense royalties. The closing of the license agreement also enables the Company to significantly expand upon its intellectual property database. This license will allow BRT to begin furthering the science, preparing it for clinical trials in the U.S., and ultimately developing improved, minimally invasive treatments for individuals with severe pain due to herniated or bulging discs.

Pursuant to the agreement, BRT has obtained an exclusive license to utilize or sublicense a specific method for culturing cells for use in repairing damaged areas. BRT has also obtained an exclusive license to utilize or sub-license a specialized needle that will be used by physicians to deliver the cells to the precise region of the disc that requires repair.

“This technology and procedure addresses an important gap in the treatment of degenerative disc disease, providing an alternative to surgery in many cases. With so many people in the U.S., and throughout the world who suffer from bulging or herniated discs, we hope that BRT will quickly emerge as a market leader in providing a minimally invasive treatment for disc repair,” commented Mark Weinreb, Chairman and CEO of BRT. “The procedure represents a potential breakthrough alternative for patients who might require back surgery or even spinal fusions – which can often fail or be unsuccessful. We believe that someday our treatment will become the standard of care for certain disc and spine related diseases.”

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a leader in developing medical procedures using cell and tissue protocols, primarily involving a patient's own stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. The Company has obtained a license for the adult stem cell treatments of disc and spine conditions, including bulging and herniated discs. The technology is an advanced stem cell injection procedure, using the patient’s own cells, that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the legs and feet. In June 2011, the Company launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem™ Program. The ThermoStem™ Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. The Company also offers facial creams and products under the Stem Pearls® brand.

#####

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:

KCSA Strategic Communications
Philip Carlson / Josh Dver
+1 212.896.1233 / +1 212.896.1239
pcarlson@kcsa.com / jdver@kcsa.com